Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent

Behavioural Pharmacology

Volumn 21, Issue 7, 2010, Pages 649-653

  Pisu, Carla ^a   Pira, Luigi ^b   Pani, Luca ^a,b  

^a CNR   (Italy)

^b PharmaNess Scarl ^*  (Italy)

Author keywords

5HT1A antagonist; Anxiety; Mouse; Quetiapine; Vogel conflict test

Indexed keywords

DIAZEPAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; QUETIAPINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRINKING; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MECHANISM; EXPERIMENTAL TEST; MALE; MOUSE; NONHUMAN; TAIL FLICK TEST; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; VOGEL CONFLICT TEST;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; ANXIETY DISORDERS; BEHAVIORAL RESEARCH; CONFLICT (PSYCHOLOGY); DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 77957325206     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833e7eab     Document Type: Article

References (46)

1. Adson DE, Kushner MG, Eiben KM, Schulz SC (2004). Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 19:121-126.
2. Ago Y, Koyama Y, Baba A, Matsuda T (2003). Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology 45:1050-1056.
3. Akimova E, Lanzenberger R, Kasper S (2009). The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 66:627-635.
4. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13:305-320.
5. Barret JE, Gleeson S (1991). Anxiolityc effects of 5HT1A agonists, 5HT3 antagonists and benzodiazepines: conflict and drug discrimination studies. In: Rogers RJ, Cooper SJ, editors. 5HT1A agonists, 5HT3 antagonists and benzodiazepines, their comparative behavioural pharmacology. Chichester: Wiley. pp. 59-105.
6. Baune BT (2008). New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. Neuropsychiatr Dis Treat 4:1181-1191.
7. Bruning CA, Prigol M, Roehrs JA, Nogueira CW, Zeni G (2009). Involvement of the serotonergic system in the anxiolytic-like effect caused by m-trifluoromethyl-diphenyl diselenide in mice. Behav Brain Res 205:511-517.
8. Campos AC, Ferreira FR, Guimaraes FS, Lemos JI (2010). Facilitation of endocannabinoid effects in the ventral hippocampus modulates anxiety -like behaviors depending on previous stress experience. Neuroscience 167:238-246.
9. Cervo L, Samanin R (1995). 5-HT1A receptor full and partial agonists and 5-HT2C (but not 5-HT3) receptor antagonists increase rates of punished responding in rats. Pharmacol Biochem Behav 52:671-676.
10. Coplan JD, Wolk SI, Klein DF (1995). Anxiety and the serotonin 1A receptor. In: Bloom FE, Kupfer DJ, editors. Psycopharmacology: the fourth generation of progress. New York: Raven; pp. 1301-1310.
11. Craske MG, Rauch SL, Ursano R, Prenoveau J, Pine DS, Zinbarg RE (2009). What is an anxiety disorder? Depress Anxiety 26:1066-1085.
12. Deakin JFW (1994). Three distinct roles of 5-HT in anxiety, panic, and depression. In: Mongomery SA, Corn TH, editors. Psychopharmacology of depression. Cambridge: British Association for Psychopharmacology Monograph. pp. 87-101.
13. Denys D, de Geus F, van Megen HJ, Westenberg HG (2004). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.
14. Gao K, Sheehan DV, Calabrese JR (2009). Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 9:1147-1158.
15. Garner M, Mohler H, Stein DJ, Mueggler T, Baldwin DS (2009). Research in anxiety disorders: from the bench to the bedside. Eur Neuropsychopharmacol 19:381-390.
16. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ (1999). Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93:1251-1262.
17. Graeff FG (2002). On serotonin and experimental anxiety. Psychopharmacology (Berl) 163:467-476.
18. Graeff FG, Viana MB, Mora PO (1997). Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 21:791-799.
19. Griebel G, Perrault G, Sanger DJ (1997). A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36:793-802.
20. Hajos-Korcsok E, McQuade R, Sharp T (1999). Influence of 5-HT1A receptors on central noradrenergic activity: microdialysis studies using ( ' )-MDL 73005EF and its enantiomers. Neuropharmacology 38:299-306.
21. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP (2003). Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 23:15-20.
22. Handley SL (1995). 5-hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 66:103-148.
23. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631.
24. Kapus GL, Gacsalyi I, Vegh M, Kompagne H, Hegedus E, Leveleki C, et al. (2008). Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues. Psychopharmacology (Berl) 198:231-241.
25. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, et al. (2008). Quetiapine as an adjunctive pharmacotherapy for the treatment of nonremitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 22:1480-1486.
26. Langerman M, Zacowski MI, Piskoun B, Grant GJ (1995). Hot plate versus tail flick: evaluation of acute tolerance to continuous morphine infusion in the rat model. J Pharmacol Toxicol Methods 34:23-27.
27. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998). Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44:1099-1117.
28. McIntyre A, Gendron A, McIntyre A (2007a). Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebocontrolled pilot study. Depress Anxiety 24:487-494.
29. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ (2007b). A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 8:1211-1219.
30. Miczek KA, Weerts EM, Vivian JA, Barros HM (1995). Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Psychopharmacology (Berl) 121:38-56.
31. Millan MJ (2000). Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 295:853-861.
32. Millan MJ, Brocco M (2003). The Vogel conflict test: procedural aspects, gammaaminobutyric acid, glutamate and monoamines. Eur J Pharmacol 463:67-96.
33. Millan MJ, Rivet JM , Canton H, Lejeune F, Gobert A, Widdowson P, Bervoets K, Brocco M, Peglion JL (1993). S 15535: a highly selective benzodioxopiperazine 5-HT1A receptor ligand which acts as an agonist and an antagonist at presynaptic and postsynaptic sites respectively, Eur J Pharmacol 230:99-102.
34. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, et al. (2009). Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 111:60-72.
35. Mogil JS, Kest B, Sadowski B, Belknap JK (1996). Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. J Pharmacol Exp Ther 276:532-544.
36. Moreira FA, Aguiar DC, Guimaraes FS (2006). Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30:1466-1471.
37. Nakamura K, Kurasawa M (2001). Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol 420:33-43.
38. Pillay NS, Stein DJ (2007). Emerging anxiolytics. Expert Opin Emerg Drugs 12:541-554.
39. Resstel LB, Souza RF, Guimaraes FS (2008). Anxiolytic-like effects induced by medial prefrontal cortex inhibition in rats submitted to the Vogel conflict test. Physiol Behav 93:200-205.
40. Sajatovic M (2003). Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Curr Psychiatry Rep 5:320-326.
41. Sandford JJ, Argyropoulos SV, Nutt DJ (2000). The psychobiology of anxiolytic drugs. Part 1: basic neurobiology. Pharmacol Ther 88:197-212.
42. Schmidt AP, Bohmer AE, Antunes C, Schallenberger C, Porciuncula LO, Elisabetsky E, et al. (2009). Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol 156:163-172.
43. Schreiber R, De Vry J (1993). 5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action? Prog Neuropsychopharmacol Biol Psychiatry 17:87-104.
44. Sharma RP, Shapiro LE (1996). The 5HT1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatric Ann 26:88-92.
45. Vogel JR, Beer B, Clody DE (1971). A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21:1-7.
46. Wang HN, Peng Y, Tan QR, Chen YC, Zhang RG, Qiao YT, et al. (2010). Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: implications for the treatment of posttraumatic stress disorder. Physiol Res 59:263-271.